Table 3. Response to chemotherapy according to RRM1 expression.
| Gemcitabine and carboplatin | Docetaxel and carboplatin | Vinorelbine and carboplatin | ||||||||||||||||
| CR | PR | SD | PD | RR | DCR | CR | PR | SD | PD | RR | DCR | CR | PR | SD | PD | RR | DCR | |
| RRM1 | ||||||||||||||||||
| Negative | 1 | 18 | 22 | 11 | 19 | 41* | 1 | 17 | 26 | 6 | 18 | 44 | 1 | 14 | 21 | 8 | 15 | 36 |
| Positive | 0 | 7 | 9 | 13 | 7 | 16* # | 0 | 10 | 12 | 5 | 10 | 22# | 0 | 11 | 11 | 5 | 11 | 22# |
*Based on Fisher’s exact test. In patients receiving gemcitabine-based therapy, the DCR of RRM1-negative patients was higher than RRM1-positive patients (P = 0.041).
#
Based on Fisher’s exact test. In patients with RRM1-positive tumors, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine-based therapy (P = 0.047 and P = 0.047, respectively).